

# Expression patterns of MMR proteins in cervical cancer uncover independent prognostic value of MSH-2

## Supplementary material

Madeleine C. van den Berg<sup>1,2</sup>, MD, Hege F. Berg<sup>1,2</sup>, PhD, Tomasz Stokowy<sup>3</sup>, PhD, Erling A. Hoivik<sup>1,2</sup>, PhD, Kathrine Woie<sup>1</sup>, MD, PhD, Hilde Engerud<sup>1,2</sup>, MD, PhD, Akinyemi I Ojesina<sup>4,5</sup>, MD, PhD, Ingfrid S. Haldorsen<sup>6,7</sup>, MD, PhD, Jone Trovik<sup>1,2</sup>, MD, PhD, Bjørn I. Bertelsen<sup>8</sup>, MD, PhD, Camilla Krakstad<sup>1,2</sup>, PhD and Mari Kyllesø Halle<sup>1,2, #</sup>, PhD

<sup>1</sup>Department of Obstetrics and Gynaecology, Haukeland University Hospital, Bergen, Norway;

<sup>2</sup>Centre for Cancer Biomarkers, Department of Clinical Science, University of Bergen, 5053 Bergen, Norway.

<sup>3</sup>Scientific Computing Group, IT Division, University of Bergen Norway.

<sup>4</sup>Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI, USA.

<sup>5</sup>Medical College of Wisconsin Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA.

<sup>6</sup>Department of Clinical Medicine, University of Bergen, Bergen, Norway.

<sup>7</sup>Mohn Medical Imaging and Visualization Centre, Department of Radiology, Haukeland University Hospital, Bergen, Norway.

<sup>8</sup>Department of Pathology, Haukeland University Hospital, 5021 Bergen, Norway

#Corresponding author:

Mari Kyllesø Halle: Glasblokkene, Blokk 1, Haukelandsbakken 15, 5009 Bergen; e-mail: [mari.halle@uib.no](mailto:mari.halle@uib.no); phone: +47 99 59 65 97; ORCID: 0000-0002-2660-8271

## Appendix A

### Methods

#### *Patient cohort*

MRIs in this study include T2-weighted sequences acquired and read in two orthogonal planes.

#### *Immunohistochemical staining*

TMA slides were dewaxed in xylene, rehydrated in graded ethanol prior to antigen retrieval in pH 9 (S-2367; Dako Denmark A/S, Glostrup, Denmark) or pH 6 (S-1699 Dako, North America) by boiling for 15 minutes. Endogenous peroxidase activity was blocked (S-2023; Dako Denmark A/S) and sections were stained for 30 min (anti MLH-1, anti MSH-2) or one hour (anti MSH-6, anti PMS-2) at room temperature with primary antibodies

Sections were then stained with horseradish peroxidase-labeled secondary anti-mouse antibody (K-4001; Dako-Denmark A/S) for 30 minutes. Finally, DAB-chromogen (K-4010; Dako Denmark A/S) was applied, the sections were counterstained with hematoxylin and dehydrated in ethanol and xylene before mounting.

#### *Evaluation of scoring*

Sections were scored using the semi-quantitative staining index (SI) method, considering both staining intensity and area of positive staining. Intensity of nuclear staining was scored as 0 = negative, 1 = weak, 2 = moderate or 3 = strong, and area of the staining was scored 0 = 0%, 1 = 1-10%, 2 = 10-50% and 3 > 50% positive staining. The SI was calculated as a product of intensity and area.


#### *Transcriptomic analyses*

GSEAs were performed within the JExpress software applying Golub (signal to noise) as scoring method and by permuting on genes (1000 permutations).

#### *Mutational analyses*


DNA was extracted from snap-frozen tumor tissue by using the AllPrep DNA/RNA Mini kit (Qiagen, Germany) in agreement with the manufacturer's protocol. The libraries were set up using KAPA Hyper Prep (100 ng input) and captured using the SeqCap EZ MedExome

(Roche, Basel, Switzerland). The Illumina HiSeq 4000 (Twist: 100 × 2) was applied for sequencing. Bwa-mem (v.0.7.17) was used to align sequences to the human genome GRCh38, executed using the dockstore-cgpmap 3.3.0 pipeline. Raw reads quality was assessed using the FASTQC and Picard software (v.2.17.0). The GATK was applied for depth and coverage analyses. MultiQC (was used to generate data quality report and control factors such as duplicate and alignment rate. Total number of sequenced reads, unique reads, covered bases and coverage per base are summarized in Supplementary Table 3). Variant calling procedure included consideration of a 1000 genomes panel of normal samples (suggested by Mutect documentation), calculation of contamination tables and finally filtering using FilterMutectCalls function. From the filtered calls we extracted variants which had “PASS” annotation. Overlap of called variants was limited to exome regions using MedExome hg38 bed files from Roche and ontarged capture with bedtools intersect (version 2.27.1). Variants were annotated using Ensembl VEP following vcf2maf instruction 1.6.21.

**Supplementary figures**

**Supplementary figure 1 - No difference in survival between patients with MMR-deficient versus proficient tumors**

**A/B:** Mismatch repair deficiency (MMR-D) did not associate with disease specific survival (A) or ≤ 10% MMR positive cells (B). P-values are given by log-rank (Mantel-Cox) test. Number in brackets indicates total number of patients/events.



**Supplementary figure 2 - MMR-deficiency is not prognostic within patients with neuroendocrine carcinomas**

No difference in survival outcomes were detected between patients with mismatch repair deficient (MMR-D) and mismatch repair proficient (MMR-P) neuroendocrine carcinomas. P-values are given by log-rank (Mantel-Cox) test. Number in brackets indicates total number of patients/number of events.

**Supplementary tables****Supplementary table 1–** Immunohistochemistry antibody information.

<b>Primary antibody</b>	<b>Supplier</b>	<b>Catalogue number</b>	<b>Dilution</b>	<b>Incubation time</b>	<b>HIER buffer</b>
<b>MLH-1</b>	Leica Biosystems	MLH1-L-CE	1 : 100	30 min	pH 9
<b>MSH-6</b>	Leica Biosystems	MSH6-L-CE	1 : 25	60 min	pH 9
<b>MSH-2</b>	Leica Biosystems	MSH2-L-CE	1 : 50	30 min	pH 6
<b>PMS-1</b>	Leica Biosystems	PMS2-L-CE	1 : 30	60 min	pH 9

HIER: Heat induced epitope retrieval

**Supplementary table 2 –** Cut-off values for the dichotomization of the staining index for the MMR proteins

<b>Protein</b>	<b>Low Range staining index (n)</b>	<b>High Range staining index (n)</b>
MLH-1	0-6 (232)	9 (232)
MSH-2	0-4 (48)	6-9 (409)
MSH-6	0-6 (175)	9 (287)
PMS-2	0-3 (177)	4-9 (272)

**Supplementary table 3** – sequencing coverage and quality statistics of the whole exome sequencing

Sample ID	Total number of sequenced reads	Total number of uniquely mapped non-duplicate reads <sup>a</sup>	Total number of covered bases (Mb) <sup>b</sup>	Median coverage per base <sup>b</sup>	Minimum coverage per base <sup>b</sup>	Maximum coverage per base <sup>b</sup>	Percentage of targeted bases with coverage $\geq 30^{b,c,d}$
T_001	169600000	110017870	11040.4	117.0	0	4773	99.0%
T_002	168000000	110679618	11103.0	115.0	0	2632	99.0%
T_003	183000000	118643264	11890.7	125.0	0	2694	99.0%
T_004	200000000	127458930	12797.0	134.0	0	3175	99.0%
T_005	165000000	108306450	10873.3	116.0	0	2615	99.0%
T_006	191600000	123306116	12359.3	129.0	0	2383	99.0%
T_007	199200000	126689030	12702.1	134.0	0	2955	99.0%
T_008	196400000	123106042	12324.4	129.0	0	3112	99.0%
T_009	203800000	130482752	13081.0	138.0	0	2446	99.0%
T_010	174400000	113401606	11380.7	121.0	0	2683	99.0%
T_011	198800000	127301438	12751.2	137.0	0	2866	99.0%
T_012	203400000	129176532	12962.0	140.0	0	2988	99.0%
T_013	216600000	136701680	13711.4	147.0	0	3085	99.0%
T_014	181800000	120305458	12073.3	129.0	0	2836	99.0%
T_015	163200000	107128796	10745.5	115.0	0	2800	99.0%
T_016	178200000	113999368	11438.6	122.0	0	2738	99.0%
T_017	183600000	124211754	12436.7	127.0	0	3595	99.0%
T_018	203400000	134600872	13456.6	142.0	0	2822	99.0%
T_019	172600000	116187898	11644.5	122.0	0	2664	99.0%
T_020	182200000	120234622	12049.2	127.0	0	2352	99.0%
T_021	210200000	136447406	13684.9	139.0	0	3025	99.0%
T_022	164600000	111760200	11198.7	117.0	0	2985	99.0%
T_023	188600000	126147470	12655.4	133.0	0	3324	99.0%
T_024	171800000	117133020	11746.8	123.0	0	2403	99.0%
T_025	196600000	134752866	13495.8	143.0	0	2965	99.0%
T_026	241200000	154958410	15526.1	161.0	0	3509	99.0%
T_027	179600000	124554334	12481.0	128.0	0	2505	99.0%
T_028	187400000	127697606	12810.2	133.0	0	2879	99.0%
T_029	200400000	138662390	13922.2	147.0	0	3358	99.0%
T_030	196000000	134378194	13474.7	132.0	0	3769	99.0%
T_031	198200000	135821092	13608.9	138.0	0	3225	99.0%
T_032	194200000	134602558	13485.1	140.0	0	3165	99.0%
T_033	228600000	144664250	14520.3	152.0	0	3923	99.0%
T_034	233200000	148220172	14874.9	158.0	0	3388	99.0%
T_035	212000000	135444592	13603.7	143.0	0	3198	99.0%
T_036	216600000	139919874	14032.1	148.0	0	3288	99.0%
T_037	209600000	134680836	13525.4	143.0	0	3408	99.0%







N_071	105800000	75028444	7250.2	74.0	0	1772	99.0%
N_072	112400000	79687240	8036.1	81.0	0	2062	99.0%
N_073	123200000	85907714	7985.4	75.0	0	2206	99.0%
N_074	119000000	84053078	8306.0	79.0	0	2095	99.0%
N_075	139600000	96152396	9469.9	90.0	0	2456	99.0%
N_076	131600000	89221870	10005.3	96.0	0	2286	99.0%
N_077	127600000	88927116	9174.2	87.0	0	2070	99.0%
N_078	136600000	94340742	7352.3	70.0	0	2410	98.0%
N_079	100800000	71907044	9169.3	85.0	0	1743	99.0%
N_080	124400000	85078162	7642.9	72.0	0	2025	99.0%
N_081	99200000	84385714	8447.7	85.0	0	2027	99.0%
N_082	115800000	96872590	9680.4	99.0	0	2307	99.0%
N_083	114000000	96598268	9676.8	97.0	0	2392	99.0%
N_084	110200000	93180314	9329.3	94.0	0	1979	99.0%
N_085	104400000	88409020	8848.6	88.0	0	2103	99.0%
N_086	85600000	72936470	7305.2	74.0	0	1872	99.0%
N_087	106000000	90173836	9030.6	90.0	0	2232	99.0%
N_088	109800000	92587178	9279.5	94.0	0	2197	99.0%
N_089	104000000	86378168	8638.3	87.0	0	2226	99.0%
N_090	104200000	87480814	8741.4	88.0	0	2209	99.0%
N_091	102600000	85605428	8558.1	86.0	0	2246	99.0%
N_092	113800000	94820612	9475.8	95.0	0	2452	99.0%
N_093	80000000	69006124	6893.6	69.0	0	1676	98.0%
N_094	94400000	79796840	7967.8	80.0	0	2383	99.0%
N_095	94000000	79430004	7933.6	80.0	0	2176	99.0%
N_096	88000000	75044702	7497.4	76.0	0	1744	99.0%

**Supplementary table 4** –MMR deficiency detected in a population based Norwegian cervical cancer patient cohort (total n=5)

Case	Age	Histological type	FIGO-18 stage	Last status (months follow-up)	MLH-1 SI	PMS-2 SI	MSH-2 SI	MSH-6 SI
<b>Patient 1</b>	62	NEC	IV	Dead from disease (3)	0	0	4	6
<b>Patient 2</b>	42	NEC	I	Alive (125)	0	0	4	9
<b>Patient 3</b>	48	NEC	III	Dead from disease (14)	0*	0*	6*	6*
<b>Patient 4</b>	57	SCC	IV	Alive (92)	2	0	1	6
<b>Patient 5</b>	48	SCC	I	Alive (174)	2	0	6	6

FIGO: International Federation of Gynecology and Obstetrics. SI: staining index, NEC: neuroendocrine carcinoma, SCC: squamous cell carcinoma, ASC: adenosquamous cell carcinoma.

\* TMA score

**Supplementary table 5** – Clinicopathological characteristics for patients with neuroendocrine carcinomas according to MMR deficiency.

<b>Variables (n)</b>	<b>MMR-P (n= 7)</b>	<b>MMR-D (n= 3)</b>	<b>p-value <sup>a</sup></b>
<i>Median age (10)</i>			0.500
< 45 years	4 (57)	1 (33)	
≥ 45 years	3 (43)	2 (67)	
<i>FIGO-18 stage (10)</i>			
I-IB1	2 (20)	2 (20)	
IB2-IV	8 (80)	8 (80)	
<i>Max tumour diameter (7)</i>			1.000
≤ 4 cm	2 (40)	1 (50)	
> 4 cm	3 (60)	1 (50)	
<i>Depth of invasion (5)</i>			1.000
Low (≤ 7 mm)	1 (33)	1 (50)	
High (> 7 mm)	2 (67)	1 (50)	
<i>Inflammatory reaction (9)</i>			0.635 <sup>b</sup>
No	3 (50)	2 (67)	
Intermediate	3 (50)	1 (33)	
Strong	0 (0)	0 (0)	
<i>Vascular space invasion (8)</i>			1.000
No	3 (75)	1 (50)	
Yes	1 (25)	1 (50)	

pMMR: proficient MMR, dMMR: deficient MMR. FIGO: Fédération Internationale de Gynécologie et d'Obstétrique. <sup>a</sup> Fisher exact, <sup>b</sup> chi-square.

**Supplementary table 6** - Clinicopathological characteristics for patients with MSH-2 high vs low tumors.

<b>Variables (n)</b>	<b>MSH-2 Low (n= 48)</b> n (%)	<b>MSH-2 High (n= 410)</b> n (%)	<b>p-value <sup>a</sup></b>
<i>Median age (458)</i>			0.585
< 45 years	22 (46)	205 (50)	
≥ 45 years	26 (54)	205 (50)	
<i>FIGO-18 stage (458)</i>			0.937
I-IB1	16 (33)	139 (34)	
IB2-IV	32 (67)	271 (66)	
<i>Max tumor diameter in MRI (243)</i>			0.587
≤ 4 cm	12 (55)	134 (61)	
> 4 cm	10 (45)	87 (39)	
<i>Histologic type (458)</i>			0.083
Squamous cell carcinoma	35 (73)	306 (75)	
Adenocarcinoma	7 (15)	79 (19)	
Adenosquamous carcinoma	4 (8)	10 (2)	
Neuroendocrine carcinoma	2 (4)	6 (2)	
Undifferentiated	0 (0)	9 (2)	
<i>Grade (452)</i>			0.876
Grade 1/2	42 (88)	350 (87)	
Grade 3	6 (12)	54 (13)	
<i>BMI (452)</i>			0.648
≤ 25	24 (9.8)	221 (55)	
> 25	23 (11.1)	184 (45)	
<i>Inflammatory reaction (442)</i>			0.425
No	8 (18)	59 (15)	
Intermediate	35 (78)	297 (75)	
Strong	2 (4)	41 (10)	
<i>Vascular space invasion (333)</i>			0.838
No	28 (68)	204 (70)	
Yes	13 (32)	88 (30)	
<i>P53 status (253)</i>			0.005
Integral	19 (54)	154 (71)	
Negative	9 (26)	17 (8)	
High	7 (20)	47 (21)	

The number of cases in each group is given followed by percentage for each column in parenthesis.

FIGO: Fédération Internationale de Gynécologie et d'Obstétrique. BMI: body mass index

<sup>a</sup> Chi-square

**Supplementary table 7** – List of top-20 enriched genesets in MSH-2 low tumors in C5 and 11 enriched genesets in Hallmarks

Gene Set	Size	ES	NES	Non pvalue	FDR (%)
<b>c5</b>					
GO_CORNIFICATION	110	0,61	3,19	0	0
GO_RESPONSE_TO_TYPE_I_INTERFERON	92	0,63	3,07	0	0
GO_T_CELL_ACTIVATION_INVOLVED_IN_IMMUNE_RESPONSE	98	0,58	2,97	0	0
GO_MHC_PROTEIN_COMPLEX	21	0,84	2,96	0	0
GO_ADAPTIVE_IMMUNE_RESPONSE	376	0,49	2,95	0	0
GO_GRANULOCYTE_MIGRATION	126	0,55	2,93	0	0
GO_ANTIGEN_BINDING	53	0,64	2,92	0	0
GO_CCR_CHEMOKINE_RECECTOR_BINDING	37	0,71	2,92	0	0
GO_NEUTROPHIL_MIGRATION	105	0,57	2,92	0	0
GO_CYTOKINE_SECRETION	207	0,51	2,91	0	0
GO_CHEMOKINE_RECECTOR_BINDING	59	0,62	2,9	0	0
GO_TYPE_2_IMMUNE_RESPONSE	35	0,7	2,9	0	0
GO_REGULATION_OF_CELL_KILLING	88	0,58	2,89	0	0
GO_INTERFERON_GAMMA_MEDIATED_SIGNALING_PATHWAY	84	0,56	2,82	0	0
GO_RESPONSE_TO_INTERFERON_GAMMA	186	0,5	2,82	0	0
GO_INTERLEUKIN_1_BETA_SECRETION	48	0,64	2,81	0	0
GO_RESPONSE_TO_PROTOZOAN	18	0,82	2,79	0	0
GO_LYMPHOCYTE_CHEMOTAXIS	56	0,61	2,78	0	0
GO_INTERLEUKIN_1_BETA_PRODUCTION	77	0,58	2,78	0	0
GO_POSITIVE_REGULATION_OF_CYTOKINE_SECRETION	126	0,52	2,78	0	0
<b>Hallmarks</b>					
HALLMARK_INTERFERON_ALPHA_RESPONSE	92	0,71	3,57	0	0
HALLMARK_INTERFERON_GAMMA_RESPONSE	195	0,63	3,55	0	0
HALLMARK_ALLOGRAFT_REJECTION	199	0,58	3,33	0	0
HALLMARK_INFLAMMATORY_RESPONSE	195	0,54	3,11	0	0
HALLMARK_TNFA_SIGNALING_VIA_NFKB	195	0,51	2,9	0	0
HALLMARK_IL6_JAK_STAT3_SIGNALING	85	0,56	2,76	0	0
HALLMARK_COMPLEMENT	193	0,35	1,95	0	0,04
HALLMARK_COAGULATION	133	0,33	1,81	0	0,11
HALLMARK_KRAS_SIGNALING_UP	190	0,32	1,81	0	0,1
HALLMARK_IL2_STAT5_SIGNALING	194	0,3	1,68	0	0,38
HALLMARK_P53_PATHWAY	194	0,28	1,55	0	0,83